LivingGLP1
Study S002301

A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Two Times a Day in Subjects With Type 2 Diabetes Mellitus Treated With Metformin Alone

Registration

Registration
NCT00039013
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE3
Masking
DOUBLE
Status
COMPLETED
Enrollment
336
Start
2002-03
Primary completion
2003-06
Lead sponsor
AstraZeneca
Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG:AC2993; DRUG:Placebo
Results posted
FALSE

Registered primary outcomes

  • Change in HbA1c (glycosylated hemoglobin) from baseline to study termination (Week 30) [Baseline (Day 1), Week 30]

Linked records (4)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0018919Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index.
Pencek R, Postgraduate medicine
2012Randomized trialPMID 22913891DOIcites ClinicalTrials.gov:NCT00039013; registry reference DERIVED:22913891
R0026474Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment.
Fineman MS, Diabetes, obesity & metabolism
2012OtherPMID 22236356DOIcites ClinicalTrials.gov:NCT00039013; registry reference DERIVED:22236356
R0025778Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus.
Ratner RE, Diabetes, obesity & metabolism
2006Randomized trialPMID 16776749DOIregistry reference RESULT:16776749
R0022664Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
DeFronzo RA, Diabetes care
2005Randomized trialPMID 15855572DOIregistry reference RESULT:15855572